Adjuvant Everolimus Fails to Stop Recurrence in Early High-Risk Breast Cancer

(MedPage Today) -- Adding mTOR inhibitor everolimus (Afinitor) to adjuvant endocrine therapy failed to improve disease-free survival (DFS) in high-risk hormone receptor-positive/HER2-negative (HR+/HER2-), a large randomized trial showed. Three...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news